Advertisement
Collaboration › Details
Fluidigm–UBS: investor conference, 201905 supply service Fluidigm presents at UBS Global Healthcare Conference NY
Period | 2019-05-21 | |
Region | New York, NY | |
Country | United States (USA) | |
Partner, 1st | Fluidigm Corporation (Nasdaq: FLDM) | |
Today | Standard BioTools Inc. (Nasdaq: LAB) | |
Group | Standard BioTools (Group) | |
Product | UBS Global Healthcare Conference 2019 New York | |
Product 2 | CyTOF® mass cytometer | |
Person | Linthwaite, S. Christopher (Chris) (Fluidigm 201610– CEO joined 201608 as COO before Thermo Fisher + Life Technologies) | |
Person 2 | Lee, Agnes (Fluidigm 201806 VP Investor Relations) | |
Fluidigm Corporation. (5/9/19). "Press Release: Fluidigm to Participate in Upcoming Health Care Investor Conferences". South San Francisco, CA.
Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in two upcoming investor conferences.
> Chris Linthwaite, President and Chief Executive Officer, will participate in a fireside chat regarding Fluidigm’s business strategy and financial performance on Tuesday, May 21, 2019 at 11:30 ET at the UBS Global Healthcare Conference in New York.
> Vikram Jog, Chief Financial Officer, is scheduled to present on Tuesday, June 4, 2019, at 1:30 pm ET regarding Fluidigm’s business strategy and financial performance at the Jefferies 2019 Healthcare Conference in New York. A breakout will follow the presentation at 2:00 pm ET.
A live webcast of the company’s fireside chat, presentation and subsequent replay will be available in the Events & Presentations section of the Company’s investor website. The webcast will be available one hour after the conclusion of the events and will be archived for 90 days following the live presentation.
About Fluidigm
Fluidigm (NASDAQ:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.
Fluidigm and the Fluidigm logo are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
Contact:
Fluidigm Corporation
Agnes Lee
Vice President, Investor Relations
650 416 7423
agnes.lee@fluidigm.com
Record changed: 2019-08-15 |
Advertisement
More documents for Standard BioTools (Group)
- [1] Standard BioTools Inc.. (8/6/24). "Press Release: Standard BioTools to Participate in Upcoming Investor Conferences". South San Francisco, CA....
- [2] Standard BioTools Inc.. (1/5/24). "Press Release: Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools". South San Francisco, CA & Boulder, CO....
- [3] Standard BioTools Inc.. (10/4/23). "Press Release: Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools". South San Francisco, CA & Boulder, CO....
- [4] Fluidigm Corporation. (4/4/22). "Press Release: Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.". South San Francisco, CA....
- [5] Fluidigm Corporation. (4/1/22). "Press Release: Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion". South San Francisco, CA....
- [6] Fluidigm Corporation. (3/28/22). "Press Release: Fluidigm Highlights the Strategic Capital Infusion by Casdin Capital and Viking Global as the Only Actionable Financing Solution". South San Francisco, CA....
- [7] Fluidigm Corporation. (1/24/22). "Press Release: Fluidigm Announces $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors and Rebranding to Standard BioTools Inc.". South San Francisco, CA....
- [8] Fluidigm Corporation. (9/2/21). "Press Release: Fluidigm to Participate in the Cantor Virtual Global Healthcare Conference". South San Francisco, CA....
- [9] SomaLogic, Inc.. (12/22/20). "Press Release: SomaLogic Adds $81M to Series A Financing Totaling $214M". Boulder, CO....
- [10] Fluidigm Corporation. (5/7/20). "Press Release: Fluidigm Expands Accessibility of Mass Cytometry and Imaging Mass Cytometry Technology with New Therapeutic Insights Services". South San Francisco, CA....
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com
Advertisement
» top